Older antipsychotic drugs – known as “conventional” antipsychotics – pose an increased risk of death when used to treat dementia in elderly patients, prompting the Food & Drug Administration (FDA) to ask the makers of these drugs to add a black box warning to their labels. In 2005, newer antipsychotic drugs, including Abilify and Risperdal, received a similar warning. The conventional antipsychotics subject to the new black box warning include:
Compazine (prochlorperazine)
Haldol (haloperidol)
Loxitane (loxapine)
Mellaril (thioridazine)
Moban (molindrone)
Navane (thithixene)
Orap (pimozide)
Prolixin (fluphenazine)
Stelazine (trifluoperazine)
Thorazine (chlorpromazine)
Tilafon (perphenazine) (more…)

